LEVOBUNOLOL HYDROCHLORIDE OPHTHALMIC SOLUTION LIQUID Canada - English - Health Canada

levobunolol hydrochloride ophthalmic solution liquid

bausch & lomb pharmaceuticals inc. - levobunolol hydrochloride - liquid - 0.50% - levobunolol hydrochloride 0.50% - beta-adrenergic agents

LEVOBUNOLOL HYDROCHLORIDE OPHTHALMIC SOLUTION LIQUID Canada - English - Health Canada

levobunolol hydrochloride ophthalmic solution liquid

alcon canada inc - levobunolol hydrochloride - liquid - 0.50% - levobunolol hydrochloride 0.50% - beta-adrenergic agents

BETAGAN 0.5 %w/v Ear Drops Solution Ireland - English - HPRA (Health Products Regulatory Authority)

betagan 0.5 %w/v ear drops solution

pco manufacturing - levobunolol hydrochloride - ear drops solution - 0.5 %w/v

BETAGAN 0.5 %w/v Eye Drops Solution Ireland - English - HPRA (Health Products Regulatory Authority)

betagan 0.5 %w/v eye drops solution

ltt pharma limited - levobunolol hydrochloride - eye drops solution - 0.5 %w/v

BETAGAN 0.5 %w/v Eye Drops Solution Ireland - English - HPRA (Health Products Regulatory Authority)

betagan 0.5 %w/v eye drops solution

b & s healthcare - levobunolol hydrochloride - eye drops solution - 0.5 %w/v

IOPIDINE apraclonidine 5mg/mL (as hydrochloride) eye drops bottle Australia - English - Department of Health (Therapeutic Goods Administration)

iopidine apraclonidine 5mg/ml (as hydrochloride) eye drops bottle

clinect pty ltd - apraclonidine hydrochloride, quantity: 5.75 mg/ml - eye drops, solution - excipient ingredients: benzalkonium chloride; sodium acetate; sodium chloride; hydrochloric acid; sodium hydroxide; purified water - to control intraocular pressure in glaucoma patients on maximally tolerated glaucoma therapy for a period of 3 months. in clinical studies the drop in intraocular pressure (iop) appeared to decrease after day 60 which may be associated with a progression of the disease or loss of effect of the drug. this phenomenon appears to be an individual occurence with a variable time of onset. as with any patient on maximally tolerated therapy (see dosage & administration), patients using apraclonidine 0.5% eye drops to delay surgery should have frequent follow-up examinations and treatment should be discontinued if iop rises significantly. in patients who have maintained a response to apraclonidine 0.5% eye drops for 3 months and a decision is made to continue treatment, safety aspects, including any evidence of corneal changes (see warnings and precautions), and iop control should be closely monitored.

Levobunolol Hydrochloride Ophthalmic Solution 0.5%"Nitten" (レボブノロール塩酸塩点眼液0.5％「ニッテン」) Japan - English - すりの適正使用協議会 RAD-AR Council, Japan

levobunolol hydrochloride ophthalmic solution 0.5%"nitten" (レボブノロール塩酸塩点眼液0.5％「ニッテン」)

rohto nitten co., ltd. - levobunolol hydrochloride - limpid and colorless to faintly orange, eye solution, (cap) bright blue-green, (bottle) brown translucent, (accompanying bag) clear [shading]

Levobunolol Hydrochloride PF Ophthalmic Solution 0.5%"NITTEN" (レボブノロール塩酸塩PF点眼液0.5％「日点」) Japan - English - すりの適正使用協議会 RAD-AR Council, Japan

levobunolol hydrochloride pf ophthalmic solution 0.5%"nitten" (レボブノロール塩酸塩pf点眼液0.5％「日点」)

rohto nitten co., ltd. - levobunolol hydrochloride - limpid and colorless to faintly orange, eye solution, (cap) bright blue-green, (bottle) brown translucent, (accompanying bag) clear [shading]

BETAGAN 0.5% LIQUIFILM OPTH.SOLN. Eye drops Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

betagan 0.5% liquifilm opth.soln. eye drops

allergan pharmaceuticals ltd - levobunolol hydrochloride - eye drops - 0.5 %

BETAGAN Ear Drops Solution 0.5 %w/v Ireland - English - HPRA (Health Products Regulatory Authority)

betagan ear drops solution 0.5 %w/v

pco manufacturing - levobunolol hydrochloride - ear drops solution - 0.5 %w/v